A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Single Dose, 2-Way, 2-Period Crossover Safety and Exploratory Efficacy Study of INP105 (POD-OLZ) for the Acute Treatment of Agitation in Adolescents and Young Adults With Autism Spectrum Disorder
Latest Information Update: 04 Oct 2023
At a glance
- Drugs Olanzapine (Primary)
- Indications Aggression; Agitation
- Focus Adverse reactions; Proof of concept
- Acronyms CALM 201
- Sponsors Impel Pharmaceuticals
Most Recent Events
- 26 Sep 2023 Status changed from active, no longer recruiting to discontinued. ( Business reason)
- 24 Feb 2023 Planned End Date changed from 1 Jul 2023 to 31 Mar 2023.
- 24 Feb 2023 Status changed from recruiting to active, no longer recruiting.